New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
00678 ETF · CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF
The 00678 Exchange Traded Fund (ETF) is provided by Capital Investment Trust Corporation. It is built to track an index: NASDAQ Biotechnology Index. The 00678 ETF provides physical exposure, so by buying it you actually own parts of all the 189 underlying holdings. The dividend policy is capitalization.
Last update Today at 1:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-3.70%
Last price
NT$35.62
1M perf.
N/A
1M flows
N/A
AuM
€7.7M
E/R
1.01%
Rating
Not rated
ESG Consensus®
00678
NT$35.62
Performance & flows
Segment for quartile rank
December 12, 2025 → March 12, 2026
Create a free account to view the flows graph
00678
NT$35.32
+2.59%
US Health Care
-1.91%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | N/A | +2.58%  | +22.13%  | +42.82% | +25.29% | -2.99% | +2.08% | +2.08% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
ISIN
TW0000067800
AuM
€7.7M
E/R
1.01%
Replication rating
Not rated
ESG Consensus®
More details
NAV
3/12/2026
NT$35.32
1D NAV change
-2.08%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
189
Inception date
1/16/2017
Jurisdiction
Taiwan
Distribution
Taiwan
Legal structure
Open-end Investment Company
Base currency
TWD
Classification
Investment strategy
Capital NASDAQ Biotechnology Index Exchang Traded Fund is an exchange-traded fund incorporated in Taiwan The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
203780
1M perf.
+2.58%
E/R
0.3%
IBB
1M perf.
-4.17%
E/R
0.44%
HTEC
1M perf.
-6.80%
E/R
0.8%
BTEC
1M perf.
-3.36%
E/R
0.35%
IBBQ
1M perf.
-3.33%
E/R
0.19%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +2.59% | +22.13% | +42.82% | +25.29% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
81.44%
United Kingdom
1.33%
Bermuda
1.31%
Ireland
1.28%
Unavailable
13.26%
Other
1.38%
Sectors
Health Care
81.16%
Unavailable
18.77%
Diversification
Total weight of top 15 holdings out of 189
Top 15 holdings
Data as of January 31, 2026
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
AMGEN-T
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
INSMED
BIOGEN INC
US04016X1019
Create a free account to view top holdings
ILLUMINA
UTD THERAPEUT
INCYTE
MODERNA INC
REVOLUTION MEDICINES INC
ROYALTY PHARMA
MEDPACE HOLDINGS INC
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Capital Investment Trust Corporation
Capital Investment Trust Corporation ID Card
Number of funds
4
Total AuM
€8.19B
Expense ratio range
0.32% - 1.08%
Average expense ratio
0.7025%
Top 4 funds by Capital Investment Trust Corporation
| AuM | ||
|---|---|---|
00937B | Capital ICE ESG 20+ Year BBB US Corporate Exchange Traded Fund | €7.37B |
00923 | Qunyi Taiwan ESG Low Carbon 50 ETF | €762M |
00643 | CAPITAL SZSE SME PRICE INDEX ETF | €47M |
00678 | CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF | €7.7M |
Frequently asked questions about 00678
What does CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF, 00678, invest in?
00678 is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does 00678 replicate?
00678 tracks the NASDAQ Biotechnology Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of 00678?
00678 carries a total expense ratio (TER) of 1.01%, indicating the annual cost for holding the fund.
When was 00678 launched?
00678 was introduced to the market on January 16, 2017. It trades on Taiwan
Who is the ETF issuer of 00678?
CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF, 00678, is provided by Capital Investment Trust Corporation. Learn more about Capital Investment Trust Corporation here.
What is the current assets under management (AUM) of 00678?
00678 oversees €7.7M in assets as of March 12, 2026.
How has 00678 performed lately?
Based on data from March 12, 2026, 00678 returned 2.58% over the last three months and 2.08% year-to-date.
Does 00678 distribute dividends?
00678 follows a capitalizing, meaning it reinvests income within the fund.
What are the main country or region exposures of 00678?
As of January 31, 2026, 00678 has significant geographic allocations in USA, United Kingdom and Bermuda.
In which sector or theme does 00678 invest in?
As of January 31, 2026, 00678 focuses largely on Health Care.
How many securities does 00678 hold and how diversified is it?
As of January 31, 2026, 00678 holds 189 positions in its portfolio, with 53.22% of assets concentrated in its top 15 holdings.
What are the main positions in 00678?
As of January 31, 2026, 00678 top three holdings include GILEAD SCIENCES, VERTEX PHARMACEUTICALS and AMGEN-T.
What is the base currency of 00678?
The base currency of 00678 is TWD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
